Shelter Pharma: No Deviation in Preferential Issue Fund Use for Q2 FY27

Shelter Pharma Ltd has confirmed that there was no deviation or variation in the utilization of proceeds from its Preferential Issue of Warrants convertible into Equity Shares for the half-year ended September 30, 2026. The funds raised, amounting to ₹2602.50 Lakhs (₹26.03 Crore), were utilized for Working Capital requirements (₹2531.20 Lakhs) and General Corporate Purposes (₹71.30 Lakhs) as originally planned. The statement, reviewed by the Audit Committee, confirms adherence to the objects approved in the Extraordinary General Meeting held on July 23, 2025. The funds were raised through a Preferential Issue of Convertible Warrants on August 6, 2025.